drugset / Trial / NCT04220307
A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, multicenter, phase II study to evaluate the anti-tumor activity, PK and immunogenicity of AK104 in patients with metastatic nasopharyngeal carcinoma who have progressed after at least 2 prior lines of systemic chemotherapy (of which one of them must be platinum-based chemotherapy).
Timeline
- Start
- 2020-04-26
- Primary completion
- 2021-05-15
- Completion
- 2023-03-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Cadonilimab | Monoclonal antibody | 15 mg/kg | Intravenous |